Bomi Italia S.p.A.

- PRESS RELEASE -

Completion of the acquisition of Farma Logistica S.r.l.

Vaprio d'Adda, 18 July 2018 - Bomi Italia S.p.A. ("Bomi" or the "Company"or the "Issuer") the parent company of Bomi Group, a market leader in the biomedical logistics sector and the management of high technology healthcare products, which is listed on the multilateral trading system of AIM Italia / Alternative Investment Market, organised and managed by Borsa Italiana S.p.A., following the Press Release of 2018 June 19th, announces that it has today completed the acquisition of 100% of the share capital of Farma Logistica S.r.l. (Farma Logistica), a company operating in the healthcare logistics and transport sector in Central-South Italy and is located in Somma Vesuviana (Naples).

This acquisition, which has been completed for a consideration of Euro 2,900,000 plus an earn-out component (of up to Euro 1,100,000) tied to the achievement of certain performance parameters to be calculated by 2021, July 18th, will allow Bomi Group to create significant synergies in its transport services network and further cross-selling opportunities, and is consistent with the Group's strategy of consolidation in Europe.

In 2017 Farma Logistica generated revenues of about Euro 5.3 million with an adjusted EBITDA (in accordance with Group IAS principles) of about Euro 0.8 million and a Net Financial Position (in accordance with Group IAS principles) of about Euro 0.4 million.

__________________________________________________________________________________________________

Bomi Italia S.p.A. is the Parent Company of Bomi Group, a world leader in the biomedical logistics sector and in the management of high technology healthcare products. It was one of the first companies to receive the "Elite" certificate issued by Borsa Italiana.

Bomi Group's activities are concentrated in the integrated logistics sector and offer a wide range of logistics services in outsourcing to companies operating in the healthcare sector, managing distribution of medical equipment, pharmaceuticals, in-vitro diagnostic equipment, reagents and implant products.

Bomi Group's portfolio of about 100 clients includes some of the world's top healthcare companies (such as the leading pharmaceutical companies and producers of healthcare devices) as well as small and medium sized companies operating at a global level in the biomedical, diagnostics and biotech industries.

Bomi Group currently has about 1,235 employees and operates through subsidiary companies and associated companies in Europe, South America, China and the United States and its services are also provided, through strategic alliances with local partners.

ISIN Ordinary Share Code: IT0005108748 - Ordinary Share Ticker: BOMI

ISIN Convertible Bond Code: IT0005114480 - Convertible Bond Ticker: BOMI20

For further information.

Bomi Italia S.p.A.

IR Top

BPER Banca S.p.A.

Investor Relator

IR & Financial Communication

Nominated Adviser

tel: +3903962781313

Tel. +39 45473883

tel: +390512756537

e.mail:investorrelator@bomigroup.com

Email: @ir@irtop.com

e.mail:bomi@bper.it

Attachments

  • Original document
  • Permalink

Disclaimer

Bomi Italia S.p.A. published this content on 18 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 July 2018 17:46:02 UTC